Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Recovery From Rocuronium 1.2 mg/kg Followed by Sugammadex (Org 25969) 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)(MK-8616-026)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) Class 1 or 2 physical status;~* 18 to 65 years of age (inclusive);~* Scheduled for elective surgical procedure under general anesthesia requiring a short duration of neuromuscular block with the use of rocuronium or succinylcholine and requiring endotracheal intubation;~* Scheduled for surgery in supine position;~* Body mass index (BMI) \< 30;~* Given written informed consent.~Exclusion Criteria:~* Has ischemic heart disease or history of myocardial infarction within the last year;~* May experience difficult intubation due to anatomical malformations;~* Known or suspected to have neuromuscular disorders impairing neuromuscular blockade and/or significant renal dysfunction;~* Known or suspected family history of malignant hyperthermia;~* Known or suspected allergy to narcotics, muscle relaxants, midazolam, anesthetics or other medications used during surgery;~* Is receiving medication known to interfere with neuromuscular blocking agents such as anticonvulsants, antibiotics and Mg2+;~* Individuals in whom the use of neostigmine and/or glycopyrrolate may be contraindicated;~* Females who are pregnant or breast-feeding;~* Females of childbearing potential who are not using an acceptable method of birth control \[condom or diaphragm with spermicide, vasectomized partner (\> 6 months), IUD, abstinence\];~* Has already participated in a sugammadex trial including Protocol 19.4.303.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Rocuronium + Sugammadex (Type: EXPERIMENTAL): Participants were to receive a single bolus dose of 1.2 mg/kg rocuronium. Three minutes after the start of the rocuronium administration, they were to receive a single bolus dose of 16.0 mg/kg sugammadex.
- Succinylcholine (Type: ACTIVE_COMPARATOR): Participants were to receive a single bolus dose of 1.0 mg/kg succinylcholine and allowed to recovery spontaneously from neuromuscular blockade.

Based on this trial design, predict the completion outcome and termination type (if applicable).